Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices

Blood Stream Infections Clinical Trial

Official title:

Testing Spread and Implementation of Novel MRSA-Reducing Practices

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01255943
• Other study ID #: HHSA290200600013
• Status: Completed
• Start date: July 2010
• Est. completion date: April 2012

Study information

• Verified date: November 2021
• Source: MaineHealth
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to implement strategies for improved efficiency and waste reduction ("Toyota Lean") and positive deviance, a social behavioral change process, utilizing frontline healthcare personnel to reduce infection bloodstream infection and MRSA infection in outpatient dialysis care. In two outpatient dialysis units, dialysis unit healthcare staff will be educated in Toyota lean techniques and conduct periodic "discovery and action" dialogues to identify and implement care process changes to reduce infection. Outcomes to be monitored will include incidence of bloodstream infections and MRSA infections of all types. Data will be assessed at quarterly intervals using interrupted time series analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 175
• Est. completion date: April 2012
• Est. primary completion date: April 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria: all hemodialysis patients at two outpatient dialysis units Exclusion Criteria:peritoneal dialysis patients

Related Conditions & MeSH terms

• Blood Stream Infections
• Communicable Diseases
• Infections
• MRSA Infections
• Sepsis

Intervention

Behavioral:
• healthcare staff processes for infection prevention
Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement

Locations

Country	Name	City	State
United States	Maine Medical Center	Portland	Maine

Sponsors (3)

Lead Sponsor	Collaborator
MaineHealth	Agency for Healthcare Research and Quality (AHRQ), Indiana University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of bloodstream infections		14 months
Secondary	Incidence of MRSA infections		14 months